Your browser doesn't support javascript.
loading
Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.
Almanza, Gonzalo; Clark, Alex E; Kouznetsova, Valentina; Olmedillas, Eduardo; Castro, Andrea; Tsigelny, Igor F; Wu, Yan; Gao, George F; Leibel, Sandra L; Bray, William; Ollmann Saphire, Erica; Carlin, Aaron F; Zanetti, Maurizio.
Afiliação
  • Almanza G; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America.
  • Clark AE; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
  • Kouznetsova V; San Diego Supercomputer Center, University of California at San Diego, La Jolla, California, United States of America.
  • Olmedillas E; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.
  • Castro A; Biomedical Informatics Program, University of California San Diego, La Jolla, California, United States of America.
  • Tsigelny IF; San Diego Supercomputer Center, University of California at San Diego, La Jolla, California, United States of America.
  • Wu Y; Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, and School of Basic Medical Sciences, Capital Medical University, Beijing, China.
  • Gao GF; Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Leibel SL; Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, United States of America.
  • Bray W; Division of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, La Jolla, California, United States of America.
  • Ollmann Saphire E; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.
  • Carlin AF; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
  • Zanetti M; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America.
PLoS Pathog ; 18(7): e1010686, 2022 07.
Article em En | MEDLINE | ID: mdl-35862442
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 4_TD Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 Limite: Animals Idioma: En Revista: PLoS Pathog Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 4_TD Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 Limite: Animals Idioma: En Revista: PLoS Pathog Ano de publicação: 2022 Tipo de documento: Article